Sorafenib rechalenge in metastatic renal cell carcinoma

BJU International

Volumn 110, Issue 6B, 2012, Pages

  Porta, Camillo ^a   Paglino, Chiara ^a   Imarisio, Ilaria ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; INDIVIDUALIZATION; KIDNEY CARCINOMA; NOTE; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMATIC ERROR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PYRIDINES;

EID: 84865493260     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10920.x     Document Type: Note

References (4)

1. Zama IN, Hutson TE, Elson P, et al,. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116: 5400-6
2. Rini BI, Escudier B, Tomczak P, et al,. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011; 378: 1931-9
3. Heng DY, Mackenzie MJ, Vaishampayan UN, et al,. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy. J Clin Oncol 2011; 29 (Suppl.): abs. 305
4. Porta C,. Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos. Eur Urol 2011; 60: 1171-2